1. Field of the Invention
The present invention relates to a method and kit for therapeutically treating injuries by inducing acoustic intracellular microstreaming by using low intensity ultrasound. More particularly, the present invention relates to a method and kit which utilizes an ultrasound contrast agent and an ergonomically constructed ultrasonic transducer for placement in proximity to an injury for therapeutically treating the injury by producing acoustic cavitation at the trauma site. The ultrasound contrast agent is introduced into the patient, preferably, the patient's blood stream, prior to emitting ultrasonic waves toward the trauma site to lower the cavitation threshold, i.e., the energy required for cavitation, to a level attainable with low intensity ultrasound.
2. Description of the Related Art
The use of ultrasound or acoustic energy to therapeutically treat and evaluate bone and tissue injuries is known. Impinging ultrasonic pulses having appropriate parameters, e.g., frequency, pulse repetition, and amplitude, for suitable periods of time and at a proper external location adjacent to a bone or tissue injury has been determined to accelerate the natural healing of, for example, bone breaks and fractures.
U.S. Pat. No. 4,530,360 to Duarte describes a basic non-invasive therapeutic technique and apparatus for applying ultrasonic pulses from an operative surface placed on the skin at a location adjacent a bone injury. The applicator described in the Duarte patent has a plastic tube which serves a grip for the operator, an RF plug attached to the plastic tube for connection to an RF source, and internal cabling connected to an ultrasonic transducer. To apply the ultrasound pulses during treatment an operator must manually hold the applicator in place until the treatment is complete. As a result, the patient is, in effect, immobilized during treatment. The longer the treatment period, the more the patient is inconvenienced. The Duarte patent as well as U.S. Pat. No. 5,520,612 to Winder et al. describe ranges of RF signal for creating the ultrasound, ultrasound power density levels, ranges of duration for each ultrasonic pulse, and ranges of ultrasonic pulse frequencies.
U.S. Pat. No. 5,003,965 to Talish et al. relates to an ultrasonic body treatment system having a body-applicator unit connected to a remote control unit by sheathed fiber optic lines. The signal controlling the duration of ultrasonic pulses and the pulse repetition frequency are generated apart from the body-applicator unit. Talish et al. also describes a mounting fixture for attaching the body-applicator unit to a patient so that the operative surface is adjacent the skin location.
It has been demonstrated that the components of acoustic energy that can effect chemical change can be thermal, mechanical (agitational) and cavitational in nature. The largest non-thermal effects are those attributed to stable cavitation and mass transfer. These, in turn, can induce acoustic microstreaming, producing shear stresses on the cellular wall and boundary layer, and in the cytosol. The latter effect, due to intracellular microstreaming, can produce an increase in the metabolic function of the cell.
Since the early sixties, the specific physical and biological mechanisms behind the therapeutic effectiveness of low intensity ultrasound have been extensively investigated. For spatial average-temporal average (SATA) intensities from 0.1–0.5 W/cm2, it is possible to produce the non-thermal, high stress mechanisms of acoustic streaming and cavitation. In vitro tests on isolated fibroblast cells have shown that the effects of ultrasound on the cells are pressure sensitive, suggesting a (stable) cavitation mechanism, caused by the rapid expansion and collapse of microbubbles. The resulting bubble oscillations, possibly including acoustic microstreaming, can generate high shear stress on the cell membrane, which can affect the cell's permeability to sodium and calcium ions. The increase in cell permeability may result in an increase in calcium uptake, an increase in protein and DNA synthesis in fibroblasts, and account for the observed activation of macrophages. The production of fibroblasts and macrophages characterizes the normal fracture repair process.
It has been determined that the cavitation threshold, i.e., the energy required for cavitation, is approximately 0.1 W/cm2 in an aqueous medium and approximately 0.2 W/cm2 in vivo. One in vivo study conducted utilizing a simulated cell membrane attributed the measured ultrasound-induced changes in the properties of cell membranes to changes in diffusion rates produced by fluid layer movement near the membrane. It has also been demonstrated that the value of micromechanical stimuli (0.5 Hz for 17 minutes, daily) significantly improves the healing of tibial fractures. One study was able to correlate this accelerated healing process with the promotion of fracture revascularization. However, for SATA intensities below 0.1 W/cm2, stable cavitation and acoustic micro-streaming seem quite unlikely. In another study, exposure to low intensity ultrasound produced increased levels of aggrecan mRNA in a rat femur model in the early stages of treatment.
In vivo test results indicate that a low SATA intensity from 30–50 mW/cm2 is highly effective in stimulating bone fracture repair. These results support the thesis that ultrasonically-induced mechanical vibrations tend to increase the permeability of the cell membrane.
In other clinical studies, preliminary results indicate that angiogenesis, the development of new blood vessels, is a key component in the initial phase in the cascade of events involved in the bone fracture healing process. The increased vascularity and the micromechanical fluid pressure appear to produce an increase in cellular calcium uptake, resulting in increased protein synthesis, thereby accelerating bone fracture healing and tissue repair.
Accordingly, there is a need for a method and kit for accelerating bone and tissue healing utilizing the scientific and anatomical observations and studies discussed above. That is, there is a need for a method and kit for accelerating bone and tissue healing by lowering the cavitation threshold to a level attainable with low intensity ultrasound to produce acoustic intracellular microstreaming. Since intracellular microstreaming can produce an increase in the metabolic functions, the method and kit would accelerate the healing process.
The method and kit of the present invention is used for therapeutically treating bone and tissue injuries using low intensity ultrasound. The method includes the steps of introducing an ultrasound contrast agent into the patient, preferably, the patient's blood stream, and impinging ultrasonic waves in proximity to an injury, wherein the ultrasound contrast agent facilitates in lowering the cavitation threshold, i.e., the energy required for cavitation, to a level attainable by the low intensity ultrasonic waves. It is preferred that the ultrasonic waves exhibit an intensity from about 0.1 to 0.5 W/cm2 to produce non-thermal, high-stress mechanisms of acoustic intracellular microstreaming and cavitation.
The present invention also provides a kit for therapeutically treating bone and tissue injuries using low intensity ultrasound. The kit includes an ultrasonic transducer assembly having at least an ultrasonic transducer, a placement module configured to be worn by a patient and to receive the ultrasonic transducer assembly, an integrated ultrasonic signal generator located in the ultrasonic transducer assembly, a main operating unit (MOU) or controller, a pouch constructed to receive the MOU, and an ultrasound contrast agent provided in a syringe or a capsule in sufficient quantity for the treatment time.
Preferably, the MOU has an internal power source for powering the signal generator circuitry, a display coupled to the signal generator circuitry to display treatment sequence data, and a keypad coupled to the signal generator circuitry to permit user operation and/or entry of data. Further, the MOU is fitted within the pouch which is reliably secured to a patient during treatment, thereby providing patient mobility. Timing control circuitry, as well as monitoring circuitry for the proper attachment and operation of the ultrasonic transducer assembly, are also housed within the MOU. A MOU envisioned for use with the present invention is described in U.S. Pat. No. 5,556,372 to Talish et al.; the contents of which are hereby incorporated by reference.
The signal generator circuitry includes a processor, means for generating a pulsed control signal, and a switch coupled to the processor for regulating the pulsed control signal. A communication interface may be connected between a communication port and the processor to provide a communication link between the ultrasonic signal generator and an external computer or modem. Preferably, the communication interface is a serial communication interface, however, a parallel interface is also contemplated. An alarm may be provided to indicate to the user that the treatment time has expired. The alarm is coupled to the processor such that when ultrasonic treatment is completed the processor activates the alarm and terminates ultrasound generation.
In operation, the MOU is electrically coupled to the at least one transducer of the ultrasonic transducer assembly for transmitting signals to the at least one transducer for controlling the same. The ultrasound contrast agent is preferably introduced into the blood stream to induce acoustic intracellular microstreaming to lower the cavitation threshold to a level attainable with the ultrasonic waves to be emitted by the at least one transducer. The at least one transducer is then excited to impinge ultrasonic waves for a predetermined period of time against the trauma site.
It is contemplated that the ultrasonic waves may be emitted away from the trauma site and reflected toward the trauma site by a bone or an implanted inorganic material, such as a metallic plate. It has been demonstrated that the acoustic intracellular microstreaming produces an increase in the metabolic functions of the cell, thereby accelerating the healing process.
Preferred embodiments of the invention are described below with reference to the drawings, which are described as follows:
The ultrasonic treatment method and kit of the present invention is used for the surgically non-invasive utilization of low intensity acoustic energy to accelerate the healing process for treating bone and tissue injuries. The present invention uses the concept that the bone fracture and wound healing process can be further enhanced and accelerated if the mechanisms of stable cavitation and microstreaming are induced within the low intensity ultrasound regime. This will have several important biological effects: (1) it will further increase the permeability of the cellular wall membrane, enhancing the diffusion process for calcium uptake and protein synthesis, (2) increase the amount of hemoglobin released, (3) effect the gene expression within the insonated tissue, and (4) assist in the removal of debris from the trauma site.
At the frequencies generally employed for therapeutic and diagnostic ultrasound, from 0.1 MHz to 10 MHz, the cavitation threshold, i.e., the energy required for cavitation, occurs at pressure levels exceeding 5 MPa However, ultrasound contrast agents having gas-filled microbubbles, with radii preferably from 0.4 to 1.0 μm, have been observed to lower the cavitation threshold to less than 0.2 MPa, a factor of more than twenty-five, when targeted or impinged with acoustic energy.
Ultrasound contrast agents are nontoxic, are usually injected intravenously, can pass through the pulmonary, cardiac and capillary circulation systems, increase the backscatter only with high tissue contrast, and recirculate through the systems during a medical examination. Most of the agents consist of gas-filled microbubbles with bubble resonance frequencies in the 0.5 to 10 MHz range which is the frequency range for most therapeutic and diagnostic ultrasound medical applications. Fortunately, these correspond to bubble sizes less than 7.0 microns, small enough to pass through pulmonary, cardiac and capillary circulations. The backscattered energy can be increased by either increasing the contrast concentrations or by causing free air bubbles to resonate within the fluid, producing scattering cross-sections several orders of magnitude larger than their geometric cross-sections.
Clinically, it has been demonstrated that ultrasound contrast agents can significantly enhance the detection of blood flow in small malignant breast tumors, in small deep vessels in the abdomen, help differentiate tumor and normal tissue vascularity, aid in the detection of ischemia or occlusion and improve the visualization of vascular stenosis. Examples of ultrasound contrast agents are Definity™ (Dupont Pharmaceuticals, Bellerica, Mass.), Sonazoid™ (Nycomed-Amersham, Oslo, Norway), Optison™ (Molecular Biosystems, Inc., San Diego, Calif.), Imagent™ (Alliance Pharmaceutical Corp., San Diego, Calif.), and SonoRx™ (Bracco Diagnostics, Princeton, N.J.).
The pressure level at which the cavitation threshold is lowered, by the use of ultrasound contrast agents having gas-filled microbubbles with radii from 0.4 to 1.0 μm, is almost equal to that defined by the spatial peak temporal average (SPTA) acoustic intensity for the Sonic Accelerated Fracture Healing (SAFHST™) ultrasonic transducer manufactured by Exogen, Inc. of Piscataway, N.J. From 1995 to 1999, a set of twenty-one measurements were made of SAFHS™ transducers at a frequency of 1.5 MHz by Sonic Technologies, located in Hatboro, Pa., resulting in a sample mean (far-field) SPTA of 110.34 mW/cm2, with an unbiased sample standard deviation of 4.02 mW/cm2.
In any given plane in the acoustic field, the SPTA acoustic intensity, I, can be expressed as:
I=[Integral of Waveform Squared]·PRF/Kf2 W/cm2,
where the term in the brackets is essentially the energy in the waveform, PRF is the pulse repetition frequency and Kf2 is often referred to in the literature as the intensity response factor. If the transmitted signal is a pulsed sine wave of rectangular envelope, given by V(t)=Vo sin 2πfct, with pulse length 2T and carrier frequency fc, then
I=Po2T(PRF)/(104 ρc)W/cm2,
where Po is the peak pressure in Pascal. The relevant parameters for soft tissue and the SAFHS® transducer are: ρ=1000 kg/m3, c=1496 m/s, PRF=1.0 kHz, T=100 μsecs and fc=1.50 MHz, resulting in the following relationship between the peak pressure (in MPa) and SPTA intensity (in mW/cm2) in tissue:
Po={0.00015×I})1/2 MPa.
For a duty cycle of 20%, a SATA intensity of 30 mW/cm2 results in a SPTA intensity of approximately 97.2 mW/cm2, which in turn, results in a peak pressure of 0.12 MPa. Therefore, by introducing microbubbles into the system, a SATA intensity from 80 to 100 mW/cm2 can produce peak pressure levels that exceed the cavitation threshold.
In line with the above mathematical relationships, the principles of the present invention entail administering an ultrasound contrast agent having gas-filled microbubbles to a patient and subsequently inducing acoustic intracellular microstreaming by transmitting acoustic energy using an ultrasonic transducer. Accordingly, the kit of the present invention includes an ergonomically constructed placement module having a strap or other fastening means for being secured to an injured part of a patient's body. At least one ultrasonic transducer assembly partially fabricated with a conductive plastic material is attached or imbedded within the placement module and properly positioned in proximity to the trauma site.
Different types of ultrasonic transducers and signals can be provided, such as those described and schematically depicted in U.S. Pat. No. 5,520,612 to Winder et al.; the contents of which are hereby incorporated by reference.
Particularly, the transducers and arrangements schematically depicted by
Turning to the figures, in particular
It is contemplated that the microbubbles can be swallowed in capsule form. The capsule can be designed to be timed-release, and the microbubbles released internally at a controlled, designated time. The required capsule, timed-release technology is well known to the pharmaceutical industry (e.g., Andryx Corporation, Fort Lauderdale, Fla., manufactures such timed-release capsules).
The placement module 14 is comprised of placement bands 20 and placement support 22. The placement support 22 includes a pocket 24 adapted for placement of the ultrasonic transducer assembly 16 therein. The placement support 22 further includes a body rest 26 having slots 30 for connecting the placement support 22 to the placement bands 20. A sponge-like material 34 lines the inner surface of the placement support 22 for providing comfort to the patient. The placement support 22 may be construed of hard plastics which may be custom molded for a particular patient.
The transducer assembly 16 includes circuitry, schematically illustrated by
In operation, the placement module 14 is positioned and secured to the patient's body as shown by
The transducer within the transducer assembly 16 is then excited for a predetermined amount of time (indicated by step 11 in
The kit 10 of the present invention permits the bubble resonance frequency, the bubble radii, the SATA intensity and the transmitting frequency of the ultrasonic waves to be controllable to significantly lower the cavitation threshold to levels produced by low intensity ultrasound. For example, the transmit frequency of the ultrasonic waves can be controlled to range from 10 kHz to 10 MHZ, the bubble radii from 0.1 to 10.0 μm, and SATA intensities from about 5 to 500 mW/cm2. It is contemplated that the optimum values for these parameters for a particular patient are predetermined and set accordingly during treatment to achieve optimum healing.
With reference to
In its simplest form, the capsule 108 exists without a sensor and associated circuitry, and is configured as a chemically-controlled timed-release system, with contrast agent(s) 104. In a more complex configuration, the delivery/release system 106 is contemplated to have the capsule 108 containing a non-lead piezoelectric sensor 110, such as polyvinylidene fluoride (PVDF), for receiving and responding to an acoustic signal, and a compartment 112 for the contrast agent(s) 104.
During operation, the ultrasonic transducer assembly 16 is applied to the skin of the body at or near the site of the bone fracture or tissue wound and activated to administer the normal therapeutic dosage. The transmitted acoustic signal is detected by the sensor 110 in the capsule 108, thereby releasing a predetermined amount of the contrast agent(s) 104 within the compartment 112 of the capsule 108. It is contemplated that the capsule 108 includes a processor which is programmed by chemical and/or electromagnetic means for releasing the agent(s) 104 at different locations of the body, in preset amounts, at multiple, predetermined time intervals. After total agent release, the remaining part of the capsule 108 is discarded naturally as a waste product.
With reference to
An alternative embodiment of the transducer assembly circuitry 17 is shown in
It will be understood that various modifications can be made to the various embodiments of the present invention herein disclosed without departing from its spirit and scope. For example, various methods of introducing the ultrasound contrast agent(s) into the patient's body are foreseen other than intravenously or in capsule form. Also, various modifications may be made in the structural configuration of the placement module and the configuration of the components used to excite the ultrasonic transducer. Therefore, the above description should not be construed as limiting the invention but merely as presenting preferred embodiments of the invention. Those skilled in the art will envision other modifications within the scope and spirit of the present invention as defined by the claims presented below.
This application is the U.S. national phase of International Application No. PCT/US00/16471 filed on 14 Jun. 2000 which claims priority to U.S. Provisional Application No. 60/139,124 filed on 14 Jun. 1999 by Alan A. Winder and Rogert J. Talish, the contents of which are incorporated herein by reference.
Filing Document | Filing Date | Country | Kind | 371c Date |
---|---|---|---|---|
PCT/US00/16471 | 6/14/2000 | WO | 00 | 3/5/2002 |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO00/76406 | 12/21/2000 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
1053782 | Dickey et al. | Jun 1913 | A |
1604870 | Asman | Oct 1926 | A |
2914829 | Willemain | Dec 1959 | A |
2920853 | Bufogle | Jan 1960 | A |
3117571 | Fry et al. | Jan 1964 | A |
3134451 | Hanssen | May 1964 | A |
3193034 | Hutchinson et al. | Jul 1965 | A |
3241375 | Canzonen | Mar 1966 | A |
3304036 | Davis | Feb 1967 | A |
3310049 | Clynes | Mar 1967 | A |
3433663 | Underwood | Mar 1969 | A |
3499437 | Balamuth | Mar 1970 | A |
3521225 | Kursman et al. | Jul 1970 | A |
3550586 | Balamuth | Dec 1970 | A |
3575050 | Lynnworth | Apr 1971 | A |
3594993 | Heyse | Jul 1971 | A |
3664626 | Sneller | May 1972 | A |
3701352 | Bosworth | Oct 1972 | A |
3714619 | Morgan et al. | Jan 1973 | A |
3729162 | Salvato | Apr 1973 | A |
3760799 | Crowson | Sep 1973 | A |
3767195 | Dimick | Oct 1973 | A |
3828769 | Mettler | Aug 1974 | A |
3855638 | Pilliar | Dec 1974 | A |
3890953 | Kraus et al. | Jun 1975 | A |
3961380 | Garr | Jun 1976 | A |
3986212 | Sauer | Oct 1976 | A |
4037592 | Kronner | Jul 1977 | A |
4105017 | Ryaby et al. | Aug 1978 | A |
4108165 | Kopp et al. | Aug 1978 | A |
4127125 | Takemoto et al. | Nov 1978 | A |
4141524 | Corvese, Jr. | Feb 1979 | A |
4164794 | Spector et al. | Aug 1979 | A |
4170045 | Estes | Oct 1979 | A |
4176664 | Talish | Dec 1979 | A |
4195517 | Kalinoski et al. | Apr 1980 | A |
4206516 | Pilliar | Jun 1980 | A |
4216766 | Duykers et al. | Aug 1980 | A |
4227111 | Cross et al. | Oct 1980 | A |
4229992 | McKee et al. | Oct 1980 | A |
4233477 | Rice et al. | Nov 1980 | A |
4266532 | Ryaby et al. | May 1981 | A |
4266533 | Ryaby et al. | May 1981 | A |
4269797 | Mikiya et al. | May 1981 | A |
4291025 | Pellico | Sep 1981 | A |
4296753 | Goudin | Oct 1981 | A |
4312536 | Lloyd | Jan 1982 | A |
4315503 | Ryaby et al. | Feb 1982 | A |
4315514 | Drewes et al. | Feb 1982 | A |
4347645 | Iseki | Sep 1982 | A |
4351069 | Ballintyn et al. | Sep 1982 | A |
4355428 | Deloison et al. | Oct 1982 | A |
4358105 | Sweeney, Jr. | Nov 1982 | A |
4361154 | Pratt, Jr. | Nov 1982 | A |
4365359 | Raab | Dec 1982 | A |
4383533 | Bhagat et al. | May 1983 | A |
4407044 | Iseki | Oct 1983 | A |
4410158 | Maffei | Oct 1983 | A |
4421119 | Pratt, Jr. | Dec 1983 | A |
4431038 | Rome | Feb 1984 | A |
4440025 | Hayakawa et al. | Apr 1984 | A |
4441486 | Pounds | Apr 1984 | A |
4446586 | Reed et al. | May 1984 | A |
4452326 | Hanssen et al. | Jun 1984 | A |
4467659 | Baumoel | Aug 1984 | A |
4476874 | Taenzer et al. | Oct 1984 | A |
4482942 | Blaisdell et al. | Nov 1984 | A |
4511921 | Harlan et al. | Apr 1985 | A |
4530360 | Duarte | Jul 1985 | A |
4536894 | Galante et al. | Aug 1985 | A |
4542539 | Rowe, Jr. et al. | Sep 1985 | A |
4542744 | Barnes et al. | Sep 1985 | A |
4550714 | Talish | Nov 1985 | A |
4556066 | Semrow | Dec 1985 | A |
4557148 | Akiyama | Dec 1985 | A |
4570487 | Gruber | Feb 1986 | A |
4570640 | Barsa | Feb 1986 | A |
4570927 | Petrofsky et al. | Feb 1986 | A |
4573996 | Kwiatek et al. | Mar 1986 | A |
4594662 | Devaney | Jun 1986 | A |
4612160 | Donlevy et al. | Sep 1986 | A |
4627429 | Tsuk | Dec 1986 | A |
4630323 | Sage et al. | Dec 1986 | A |
4644942 | Sump | Feb 1987 | A |
4646725 | Moasser | Mar 1987 | A |
4657543 | Langer et al. | Apr 1987 | A |
4669483 | Hepp et al. | Jun 1987 | A |
4677438 | Michiguchi et al. | Jun 1987 | A |
4680967 | Rost | Jul 1987 | A |
4687195 | Potts | Aug 1987 | A |
4689986 | Carson et al. | Sep 1987 | A |
4708127 | Abdelghani | Nov 1987 | A |
4710655 | Masaki | Dec 1987 | A |
4725272 | Gale | Feb 1988 | A |
4726099 | Card et al. | Feb 1988 | A |
4763661 | Sommer et al. | Aug 1988 | A |
4770184 | Greene, Jr. et al. | Sep 1988 | A |
4774959 | Palmer et al. | Oct 1988 | A |
RE32782 | Pratt, Jr. | Nov 1988 | E |
4782822 | Ricken | Nov 1988 | A |
4787070 | Suzuki et al. | Nov 1988 | A |
4787888 | Fox | Nov 1988 | A |
4792336 | Hlavacek et al. | Dec 1988 | A |
4802477 | Gabbay | Feb 1989 | A |
4830015 | Okazaki | May 1989 | A |
4836316 | Carnevale et al. | Jun 1989 | A |
4855911 | Lele et al. | Aug 1989 | A |
4858599 | Halpern | Aug 1989 | A |
4867169 | Machida et al. | Sep 1989 | A |
4891849 | Robinson | Jan 1990 | A |
4905671 | Senge et al. | Mar 1990 | A |
4913157 | Pratt, Jr. et al. | Apr 1990 | A |
4917092 | Todd et al. | Apr 1990 | A |
4917376 | Lo | Apr 1990 | A |
4920966 | Hon et al. | May 1990 | A |
4926870 | Brandenburger | May 1990 | A |
4928959 | Bassett et al. | May 1990 | A |
4930358 | Motegi et al. | Jun 1990 | A |
4932951 | Liboff et al. | Jun 1990 | A |
4933230 | Card et al. | Jun 1990 | A |
4936303 | Detwiler et al. | Jun 1990 | A |
4941474 | Pratt, Jr. | Jul 1990 | A |
4947853 | Hon | Aug 1990 | A |
4979501 | Valchanov et al. | Dec 1990 | A |
4982730 | Lewis, Jr. | Jan 1991 | A |
4984462 | Hass, Jr. et al. | Jan 1991 | A |
4986275 | Ishida et al. | Jan 1991 | A |
4993413 | McLeod et al. | Feb 1991 | A |
4995883 | Demane et al. | Feb 1991 | A |
5000183 | Bonnefous | Mar 1991 | A |
5000442 | Dalebout et al. | Mar 1991 | A |
5003965 | Talish et al. | Apr 1991 | A |
5004476 | Cook | Apr 1991 | A |
5016641 | Schwartz | May 1991 | A |
5018285 | Zolman et al. | May 1991 | A |
5046484 | Bassett et al. | Sep 1991 | A |
5054490 | Rossman et al. | Oct 1991 | A |
5067940 | Liboff et al. | Nov 1991 | A |
5080672 | Bellis | Jan 1992 | A |
5088976 | Liboff et al. | Feb 1992 | A |
5099702 | French | Mar 1992 | A |
5100373 | Liboff et al. | Mar 1992 | A |
5103806 | McLeod et al. | Apr 1992 | A |
5106361 | Liboff et al. | Apr 1992 | A |
5107853 | Plyter | Apr 1992 | A |
5108452 | DeMane et al. | Apr 1992 | A |
5133420 | Smith | Jul 1992 | A |
5134999 | Osipov | Aug 1992 | A |
5139498 | Astudillo Ley | Aug 1992 | A |
5140988 | Stouffer et al. | Aug 1992 | A |
5143069 | Kwon et al. | Sep 1992 | A |
5143073 | Dory | Sep 1992 | A |
5154189 | Oberlander | Oct 1992 | A |
5163598 | Peters et al. | Nov 1992 | A |
5172692 | Kulow et al. | Dec 1992 | A |
5178134 | Vago | Jan 1993 | A |
5181512 | Viebach et al. | Jan 1993 | A |
5184605 | Grzeszykowski | Feb 1993 | A |
5186162 | Talish et al. | Feb 1993 | A |
5191880 | McLeod et al. | Mar 1993 | A |
5197475 | Antich et al. | Mar 1993 | A |
5201766 | Georgette | Apr 1993 | A |
5209221 | Riedlinger | May 1993 | A |
5211160 | Talish et al. | May 1993 | A |
5230334 | Klopotek | Jul 1993 | A |
5230345 | Curran et al. | Jul 1993 | A |
5230646 | Thorup | Jul 1993 | A |
5230921 | Waltonen et al. | Jul 1993 | A |
5235981 | Hascoet et al. | Aug 1993 | A |
5254123 | Bushey | Oct 1993 | A |
5259384 | Kaufman et al. | Nov 1993 | A |
5269306 | Warnking et al. | Dec 1993 | A |
5273028 | McLeod et al. | Dec 1993 | A |
5280728 | Sato et al. | Jan 1994 | A |
5284143 | Rattner | Feb 1994 | A |
5285788 | Arenson et al. | Feb 1994 | A |
5295931 | Dreibelbis et al. | Mar 1994 | A |
5301683 | Durkan | Apr 1994 | A |
5307284 | Brunfeldt et al. | Apr 1994 | A |
5309898 | Kaufman et al. | May 1994 | A |
5310408 | Schryver et al. | May 1994 | A |
5314401 | Tepper | May 1994 | A |
5316000 | Chapelon et al. | May 1994 | A |
5318561 | McLeod et al. | Jun 1994 | A |
5318779 | Hakamatsuka et al. | Jun 1994 | A |
5322067 | Prater et al. | Jun 1994 | A |
5323769 | Bommannan et al. | Jun 1994 | A |
5327890 | Matura et al. | Jul 1994 | A |
5330481 | Hood et al. | Jul 1994 | A |
5330489 | Green et al. | Jul 1994 | A |
5334214 | Putnam | Aug 1994 | A |
5339804 | Kemp | Aug 1994 | A |
5340510 | Bowen | Aug 1994 | A |
5351389 | Erickson et al. | Oct 1994 | A |
5363850 | Soni et al. | Nov 1994 | A |
5366465 | Mirza | Nov 1994 | A |
5367500 | Ng | Nov 1994 | A |
5368044 | Cain et al. | Nov 1994 | A |
5376065 | McLeod et al. | Dec 1994 | A |
5380269 | Urso | Jan 1995 | A |
5386830 | Powers et al. | Feb 1995 | A |
5393296 | Rattner | Feb 1995 | A |
5394877 | Orr et al. | Mar 1995 | A |
5394878 | Frazin et al. | Mar 1995 | A |
5398290 | Brethour | Mar 1995 | A |
5400795 | Murphy et al. | Mar 1995 | A |
5405389 | Conta et al. | Apr 1995 | A |
5409446 | Rattner | Apr 1995 | A |
RE34959 | Potts | May 1995 | E |
5413550 | Castel | May 1995 | A |
5415167 | Wilk | May 1995 | A |
5417215 | Evans et al. | May 1995 | A |
5424550 | Kawano et al. | Jun 1995 | A |
5425954 | Thompson et al. | Jun 1995 | A |
5431612 | Holden | Jul 1995 | A |
5434827 | Bolorforosh | Jul 1995 | A |
5441051 | Hileman et al. | Aug 1995 | A |
5441058 | Fareed | Aug 1995 | A |
5448994 | Iinuma | Sep 1995 | A |
5460595 | Hall et al. | Oct 1995 | A |
5466215 | Lair et al. | Nov 1995 | A |
5468220 | Sucher | Nov 1995 | A |
5476438 | Edrich et al. | Dec 1995 | A |
5478306 | Stoner | Dec 1995 | A |
5484388 | Bassett et al. | Jan 1996 | A |
5492525 | Gibney | Feb 1996 | A |
5495846 | Uehara et al. | Mar 1996 | A |
5496256 | Bock et al. | Mar 1996 | A |
5501657 | Feero | Mar 1996 | A |
5507800 | Strickland | Apr 1996 | A |
5507830 | DeMane et al. | Apr 1996 | A |
5509933 | Davidson et al. | Apr 1996 | A |
5520612 | Winder et al. | May 1996 | A |
5524624 | Tepper et al. | Jun 1996 | A |
5526815 | Granz et al. | Jun 1996 | A |
5541489 | Dunstan | Jul 1996 | A |
5547459 | Kaufman et al. | Aug 1996 | A |
5556372 | Talish et al. | Sep 1996 | A |
5578060 | Pohl et al. | Nov 1996 | A |
5615466 | Safari et al. | Apr 1997 | A |
5626554 | Ryaby et al. | May 1997 | A |
5626630 | Markowitz et al. | May 1997 | A |
5630837 | Crowley | May 1997 | A |
D380440 | Talish et al. | Jul 1997 | S |
5644093 | Wright et al. | Jul 1997 | A |
5648941 | King | Jul 1997 | A |
5656016 | Ogden | Aug 1997 | A |
5665141 | Vago | Sep 1997 | A |
5680863 | Hossack et al. | Oct 1997 | A |
5690608 | Watanabe et al. | Nov 1997 | A |
5691960 | Gentilman et al. | Nov 1997 | A |
5699803 | Carodiskey | Dec 1997 | A |
5702353 | Guzzini et al. | Dec 1997 | A |
5702389 | Taylor et al. | Dec 1997 | A |
5706818 | Gondo | Jan 1998 | A |
5708236 | Shaanan et al. | Jan 1998 | A |
5721400 | Haraldsson et al. | Feb 1998 | A |
5725482 | Bishop | Mar 1998 | A |
5728095 | Taylor et al. | Mar 1998 | A |
5730705 | Talish et al. | Mar 1998 | A |
5738625 | Gluck | Apr 1998 | A |
5741317 | Ostrow | Apr 1998 | A |
5743862 | Izumi | Apr 1998 | A |
5755746 | Lifshey et al. | May 1998 | A |
5762616 | Talish | Jun 1998 | A |
5779600 | Pape | Jul 1998 | A |
5785656 | Chiabrera et al. | Jul 1998 | A |
5818149 | Safari et al. | Oct 1998 | A |
5829437 | Bridges | Nov 1998 | A |
5843741 | Wong et al. | Dec 1998 | A |
5856622 | Yamamoto et al. | Jan 1999 | A |
5868649 | Erickson et al. | Feb 1999 | A |
5871446 | Wilk | Feb 1999 | A |
5886302 | Germanton et al. | Mar 1999 | A |
5891143 | Taylor et al. | Apr 1999 | A |
5899425 | Corey Jr. et al. | May 1999 | A |
5904659 | Duarte et al. | May 1999 | A |
5906580 | Kline et al. | May 1999 | A |
5954675 | Dellagatta | Sep 1999 | A |
5957814 | Eschenbach | Sep 1999 | A |
5962790 | Lynnworth et al. | Oct 1999 | A |
5971984 | Taylor et al. | Oct 1999 | A |
5997490 | McLeod et al. | Dec 1999 | A |
6019710 | Dalebout et al. | Feb 2000 | A |
6022349 | McLeod et al. | Feb 2000 | A |
6028066 | Unger | Feb 2000 | A |
6030386 | Taylor et al. | Feb 2000 | A |
6048323 | Hon | Apr 2000 | A |
6050943 | Slayton et al. | Apr 2000 | A |
6061597 | Rieman et al. | May 2000 | A |
6065350 | Hill et al. | May 2000 | A |
6068596 | Weth et al. | May 2000 | A |
6080088 | Petersen et al. | Jun 2000 | A |
6082181 | Greenwood | Jul 2000 | A |
6086078 | Ferez | Jul 2000 | A |
6088613 | Unger | Jul 2000 | A |
6093135 | Huang | Jul 2000 | A |
6105431 | Duffill et al. | Aug 2000 | A |
6165144 | Talish et al. | Dec 2000 | A |
6179797 | Brotz | Jan 2001 | B1 |
6190336 | Duarte et al. | Feb 2001 | B1 |
6206843 | Iger et al. | Mar 2001 | B1 |
6213958 | Winder | Apr 2001 | B1 |
6234975 | McLeod et al. | May 2001 | B1 |
6234990 | Rowe et al. | May 2001 | B1 |
6258020 | Lopez | Jul 2001 | B1 |
6261221 | Tepper et al. | Jul 2001 | B1 |
6261249 | Talish et al. | Jul 2001 | B1 |
6264650 | Hovda et al. | Jul 2001 | B1 |
6273864 | Duarte et al. | Aug 2001 | B1 |
6311402 | Brandl et al. | Nov 2001 | B1 |
6322527 | Talish | Nov 2001 | B1 |
6355006 | Ryaby et al. | Mar 2002 | B1 |
6360027 | Hossack et al. | Mar 2002 | B1 |
6394955 | Perlitz | May 2002 | B1 |
6397683 | Hagenmeyer et al. | Jun 2002 | B1 |
6406443 | Talish | Jun 2002 | B1 |
6436060 | Talish | Aug 2002 | B1 |
6443898 | Unger et al. | Sep 2002 | B1 |
6464687 | Ishikawa et al. | Oct 2002 | B1 |
6503214 | Talish | Jan 2003 | B1 |
6524261 | Talish et al. | Feb 2003 | B2 |
6685656 | Duarte et al. | Feb 2004 | B1 |
6733468 | Talish | May 2004 | B2 |
6932308 | Talish et al. | Aug 2005 | B2 |
6960173 | Babaev | Nov 2005 | B2 |
20020016557 | Duarte | Feb 2002 | A1 |
20020068871 | Mendlein et al. | Jun 2002 | A1 |
20020103448 | Babaev | Aug 2002 | A1 |
20020115960 | Redding, Jr. | Aug 2002 | A1 |
20020156400 | Babaev | Oct 2002 | A1 |
20020190136 | Babaev | Dec 2002 | A1 |
20030013956 | Michaeli | Jan 2003 | A1 |
20030153848 | Talish | Aug 2003 | A1 |
20030153849 | Huckle | Aug 2003 | A1 |
20040127790 | Lang et al. | Jul 2004 | A1 |
20050096548 | Talish | May 2005 | A1 |
20060106424 | Bachem | May 2006 | A1 |
Number | Date | Country |
---|---|---|
199950292745022 | Feb 2000 | AU |
1328485 | Apr 1994 | CA |
3639263 | Jun 1987 | DE |
19613425 | Jan 1997 | DE |
298 11 185 | Oct 1998 | DE |
41 11 055 | Oct 2001 | DE |
0 181 506 | May 1986 | EP |
331 348 | Sep 1989 | EP |
0 425 765 | May 1991 | EP |
0 536 875 | Apr 1993 | EP |
0 679 371 | Nov 1995 | EP |
0 695 559 | Feb 1996 | EP |
2156983 | Oct 1985 | GB |
2277448 | Nov 1994 | GB |
2 303 552 | Feb 1997 | GB |
62-47359 | Mar 1987 | JP |
4-82567 | Mar 1992 | JP |
4-82568 | Mar 1992 | JP |
4-82569 | Mar 1992 | JP |
5-269159 | Oct 1993 | JP |
WO 8503449 | Aug 1985 | WO |
WO 8800845 | Feb 1988 | WO |
WO 8802250 | Apr 1988 | WO |
WO 9006720 | Jun 1990 | WO |
WO 9413411 | Jun 1994 | WO |
WO 9503744 | Feb 1995 | WO |
WO 9533416 | Dec 1995 | WO |
WO 9625112 | Aug 1996 | WO |
WO 9625888 | Aug 1996 | WO |
WO 9733649 | Sep 1997 | WO |
WO 9810729 | Mar 1998 | WO |
WO 9829036 | Jul 1998 | WO |
WO 9834578 | Aug 1998 | WO |
WO 9847570 | Oct 1998 | WO |
WO 9918876 | Apr 1999 | WO |
WO 9922652 | May 1999 | WO |
WO 9948621 | Sep 1999 | WO |
WO 9956829 | Nov 1999 | WO |
WO 0003663 | Jan 2000 | WO |
WO 0028925 | May 2000 | WO |
WO 0067846 | Nov 2000 | WO |
WO 0071207 | Nov 2000 | WO |
WO 0076406 | Dec 2000 | WO |
Number | Date | Country | |
---|---|---|---|
60139124 | Jun 1999 | US |